"Not so Different:" The Supreme Court and US Biosimilars

Those who follow the biosimilars space closely are aware that, in the context of the US market, legal concerns regarding biosimilars can be just as regulatory ones in informing how drug makers do business. 

One recent case that impacts on upon the biosimilars market was recently heard before the before the United States Supreme Court, and the outcome of the case will potentially impact drug makers seek patent protection for various aspects of their products.

In order to take a deeper dive into the case, and hear an expert perspective on its far-reaching impacts, this week, we’re speaking with Ha Kung Wong, JD, a partner at Venable LLP and an advisory board member for The Center for Biosimilars.®